Kerala State Drugs and Pharmaceuticals Ltd
(A Govt. of Kerala Enterprise)
KALAVOOR, ALAPPUZHA
Phone :0477-2258184 (Extn:207) ; Email :purchase@ksdp.in
Web :http://www.ksdp.co.in

KSDP/PS/SQ/2026-27/400435/T-069 **6-8-2026**

Notice inviting sealed quotation for Magnesium sterarateIP(Make JR Pharma) -500kg

Quotations are invited for the supply of undermentioned goods/ services as per the attached specifications on FOR destination basis at our factory site at Kalavoor,Alapuzha, Kerala state

Sl No.	ITEM CODE & DESCRIPTION	UNIT	QUANTITY	EMD	TENDER FEES
1	10100034 Magnesium Stearate IP (Make JR Pharma)	KG	500.000	Rs. 1500	Rs.448

Quotations should be submitted as per the Proforma given below on your letter head.

Sl No.	Name of item	Make	Rate per unit (including freight, if any)	GST %	Offer validity	Remarks, if any

Due Date/Time : 17-Aug-26 / 12.30PM **Opening Date/Time : 18-Aug-26 / 12.30 PM**

Separate demand drafts should be submitted for Tender fee & EMD in favour of Kerala State Drugs &Pharmaceuticals Ltd payable at Alappuzha, Kerala.
***MSME/Udyam Registration companies will be onexemption from EMD & Tender fee. Offer validity*:**
Minimum 7 days offer validity from the date of closure of bidsubmission. Quotation received with offer validity less than 7 days from the date of closure of bid submission will be entirely rejected.
Please Submit Your Lowest Offer in a Sealed Cover Superscribing 'SEALED QUOTATION FOR THE SUPPLY OF Magnesium stearate IP(Make JR Pharma). DUE ON 17.08.2026' on or before 17.08.2026, 12.30 PM to the Office of the Managing Director, Kerala State Drugs& Pharmaceuticals Ltd, Kalavoor - P.O, Alappuzha - 688522, in two cover system.
1 st cover: should comprise of Technical bid. Must submit COA & other relevant documents for technical evaluation.
2 nd cover: Should comprise of price bid.
Quotations received in any other mode or not as per the prescribed format will be rejected.

TERMS & CONDITIONS

1.Payment terms :_ **30 days after the receipt of the material along with documents, subject to approval from user department.**

2.Mode of payment:_ **E-Payment.**

3.Delivery Period:_ **Supply should be effected within 15 days on award of PO**

4.Special instructions:_ **Bidder's stamp should be on COA**

HOD - Purchase

	KERALA STATE DRUGS AND PHARMACEUTICALS LTD, KALAVOOR PO, ALAPPUZHA, KERALA-688522			
Raw Material Specification				
Name of the Material: : **MAGNESIUM STEARATE I.P.**				
SOP No:	KSDP/SOP/SPEC01	Spec. No:	KSDP/R/SPEC01/49	
Effective date:	01/04/2026	Revision No:	04	Page 1 of 2
		Item code:	10100034	

Sl.No.	TESTS	SPECIFICATION
1	Description	A very fine, light, white powder; slippery to touch
2	Identification	A. The solution gives the reactions of magnesium B. By HPLC
3	Acidity or Alkalinity	Not more than 0.05 ml of 0.1 M HCL or 1M Sodium hydroxide is required to change the colour of the solution
4	Related content of steric acid and palmitic acid	By gas chromatography
5	Limit of Cadmium	Not more than 3 ppm
6	Limit of Lead	Not more than 10 ppm
7	Limit of Nickel	Not more than 5 ppm
8	Chlorides	Not more than 0.1%
9	Sulphates	Not more than 1%

Prepared by	Checked by	Reviewed By	Approved By	
Officer QA	Head QC	Head Production	Head QA	
01/04/2026	01/04/2026	01/04/2026	01/04/2026	MASTER COPY UNCONTROLLED COPY

	KERALA STATE DRUGS AND PHARMACEUTICALS LTD, KALAVOOR PO, ALAPPUZHA, KERALA-688522			
Raw Material Specification				
Name of the Material: : **MAGNESIUM STEARATE I.P.**				
SOP No:	KSDP/SOP/SPEC01	Spec. No:	KSDP/R/SPEC01/49	
Effective date:	01/07/2026	Revision No:	04	Page 2 of 2
		Item code:	10100034	

10	Loss on drying	Not more than 6.0%, drying in an oven at 105°
11	Assay	Not less than 4.0% and not more than 5.0%, calculated on the dried basis
12	Microbial contamination	A. Total aerobic viable count-not more than 10^3 cfu per g B. Total fungal count-not more than 5×10^2 cfu per g C. Escherichia coli - absent /g D. Salmonella species - absent/10g
13	Specific surface area	0.05-0.15, using outgassing conditions of 2 hours at 40°
14	Elemental impurities	Shall comply with the Elemental impurities specified in Table 3.0 of I.P. 2026

The product complies to I.P. 2026 with respect to above tests.

Note: • This raw material is used in the manufacture of products intended for oral administration

• Manufacturer should provide concentration of each element present in the material (concentration as µg/g)

Prepared by	Checked by	Reviewed By	Approved By	
Officer QA	Head QC	Head Production	Head QA	
				MASTER COPY UNCONTROLLED COPY
01/07/2026	01/07/2026	01/07/2026	01/07/2026	